Abstract:JD$.$com, one of the world's largest e-commerce platforms, serves over 700 million active users and millions of merchants, with a catalog of tens of billions of SKUs. At this scale, high-quality, structured item knowledge underpins a better consumer experience, lower management costs, and higher operational efficiency-yet producing and serving it poses three industrial-scale challenges: fast-emerging concepts, high-quality knowledge production for massive SKUs, and diverse downstream requirements. To address these challenges, we present the JD Oxygen AI Item Center (Oxygen AIIC), an industrial-scale platform built on LLMs/VLMs for item-knowledge production and service. Oxygen AIIC is built around four core pillars: (i) ontology engineering driven by efficient human-AI collaboration, which supports the dynamic evolution and agile expansion of an ontology with millions of entries; (ii) a "Semantic Search then Discrimination"(S2D) knowledge identification architecture that, combined with throughput improvement strategies, enables scalable, extensible, and high-throughput AI Item Library production for tens of billions of SKUs; (iii) self-evolving item-understanding LLMs/VLMs that improve in a stable and controllable manner, enabling knowledge production with 94.2% precision and 82.8% recall; and (iv) a unified item tunnel that serves as the data and service hub. Oxygen AIIC now covers tens of thousands of JD categories and processes hundreds of millions of item updates per day on Huawei Ascend NPUs. It has accumulated hundreds of billions of item-knowledge assets. Deployed across core business scenarios-including search, recommendation, operations, category planning-Oxygen AIIC has delivered measurable gains at scale. Search-traffic coverage reaches 80.4%, item-information quality issues drop by 37%, the automated fill rate of core attributes during item listing exceeds 80%.
Abstract:Objective: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by unpredictable flares. This study aimed to develop a novel proteomics-based risk prediction model specifically for Asian SLE populations to enhance personalized disease management and early intervention. Methods: A longitudinal cohort study was conducted over 48 weeks, including 139 SLE patients monitored every 12 weeks. Patients were classified into flare (n = 53) and non-flare (n = 86) groups. Baseline plasma samples underwent data-independent acquisition (DIA) proteomics analysis, and phenome-wide Mendelian randomization (PheWAS) was performed to evaluate causal relationships between proteins and clinical predictors. Logistic regression (LR) and random forest (RF) models were used to integrate proteomic and clinical data for flare risk prediction. Results: Five proteins (SAA1, B4GALT5, GIT2, NAA15, and RPIA) were significantly associated with SLE Disease Activity Index-2K (SLEDAI-2K) scores and 1-year flare risk, implicating key pathways such as B-cell receptor signaling and platelet degranulation. SAA1 demonstrated causal effects on flare-related clinical markers, including hemoglobin and red blood cell counts. A combined model integrating clinical and proteomic data achieved the highest predictive accuracy (AUC = 0.769), surpassing individual models. SAA1 was highlighted as a priority biomarker for rapid flare discrimination. Conclusion: The integration of proteomic and clinical data significantly improves flare prediction in Asian SLE patients. The identification of key proteins and their causal relationships with flare-related clinical markers provides valuable insights for proactive SLE management and personalized therapeutic approaches.